58 min
Omniscient Neurotechnology: Connectomics, a Deeper Understanding of the Brain The Bleeding Edge of Digital Health
-
- Health & Fitness
In this week’s episode, host Mike Moore speaks with Stephen Scheeler, the CEO and Managing Director of brain data company Omniscient Neurotechnology. Omniscient uses aritifical intelligence and a new field of neurotechnology called connectomics to create a digital map of the brain, known as a connectome, to better understand and eventually design unique treatments for conditions like depression, Alzheimer’s, schizophrenia and stroke. Today, Stephen talks about how brain mapping works, the science behind connectomics, and the vast human potential Omniscient Neurotechnology is hoping to unlock. Notable Quotes“They said, this changes everything. This changes our understanding of the human brain so fundamentally that it's gonna unlock all kinds of human potential over the next, you know, hundred years. And when you have people with this caliber tell you those things, you take pause. And so we started to talk about how we could maybe work together. I started helping them figure out their business model. I went to China to talk to some of the researchers that were already working in that market. And I got more and more fascinated and just saw the potential of what we were trying to build. So I kind of got more and more involved.” – Stephen (10:35)“Everybody, every wiring, every building is a little different. And so what we do is we bring those wiring maps. We build those maps so that if you have pain or you forgot where you left your keys, or you're feeling a little anxious or depressed or whatever, if you're suicidal, if it's that severe, we can map that. And we can show where in your connectome, in your wiring, the problem lies. And so that's a complete transformation for everything we do about the human brain today.” – Stephen (15:31)In This Episode(01:33) Stephen’s background(04:15) The genesis of Omniscient Neurotechnology(08:45) Neuroscience, AI and the field of connectomics (13:01) What is connectomics? (16:16) Connectomics and mental health treatment(17:31) How brain mapping works(27:10) The economic benefits and human potential of Omniscient Neurotechnology(29:44) Psychedelics and neuroscience(35:26) The surgical implications(48:56) The future of Omniscient(51:30) Omniscient’s biggest challengesOur GuestStephen Scheeler is the CEO and Managing Director of brain data company Omniscient Neurotechnology. Previously, he served as the CEO of Facebook for Australia and New Zealand. Stephen is also the founder of global advisory The Digital CEO, Senior Advisor to McKinsey & Company, and Executive-in-Residence at Asia-Pacific’s leading business school, the Australian Graduate School of Management. He has advised the leaders of Qantas, Suncorp, Telstra, Wesfarmers, AMP, CUB, Brambles, Google, and the Australian Government. Stephen is also a member of the Australian Prime Minister's Knowledge Nation 100 as one of Australia’s top innovation leaders.
Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health
In this week’s episode, host Mike Moore speaks with Stephen Scheeler, the CEO and Managing Director of brain data company Omniscient Neurotechnology. Omniscient uses aritifical intelligence and a new field of neurotechnology called connectomics to create a digital map of the brain, known as a connectome, to better understand and eventually design unique treatments for conditions like depression, Alzheimer’s, schizophrenia and stroke. Today, Stephen talks about how brain mapping works, the science behind connectomics, and the vast human potential Omniscient Neurotechnology is hoping to unlock. Notable Quotes“They said, this changes everything. This changes our understanding of the human brain so fundamentally that it's gonna unlock all kinds of human potential over the next, you know, hundred years. And when you have people with this caliber tell you those things, you take pause. And so we started to talk about how we could maybe work together. I started helping them figure out their business model. I went to China to talk to some of the researchers that were already working in that market. And I got more and more fascinated and just saw the potential of what we were trying to build. So I kind of got more and more involved.” – Stephen (10:35)“Everybody, every wiring, every building is a little different. And so what we do is we bring those wiring maps. We build those maps so that if you have pain or you forgot where you left your keys, or you're feeling a little anxious or depressed or whatever, if you're suicidal, if it's that severe, we can map that. And we can show where in your connectome, in your wiring, the problem lies. And so that's a complete transformation for everything we do about the human brain today.” – Stephen (15:31)In This Episode(01:33) Stephen’s background(04:15) The genesis of Omniscient Neurotechnology(08:45) Neuroscience, AI and the field of connectomics (13:01) What is connectomics? (16:16) Connectomics and mental health treatment(17:31) How brain mapping works(27:10) The economic benefits and human potential of Omniscient Neurotechnology(29:44) Psychedelics and neuroscience(35:26) The surgical implications(48:56) The future of Omniscient(51:30) Omniscient’s biggest challengesOur GuestStephen Scheeler is the CEO and Managing Director of brain data company Omniscient Neurotechnology. Previously, he served as the CEO of Facebook for Australia and New Zealand. Stephen is also the founder of global advisory The Digital CEO, Senior Advisor to McKinsey & Company, and Executive-in-Residence at Asia-Pacific’s leading business school, the Australian Graduate School of Management. He has advised the leaders of Qantas, Suncorp, Telstra, Wesfarmers, AMP, CUB, Brambles, Google, and the Australian Government. Stephen is also a member of the Australian Prime Minister's Knowledge Nation 100 as one of Australia’s top innovation leaders.
Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health
58 min